OB/Gyn
Ovarian Cancer
More in Ovarian Cancer
Moreover, a significant proportion do not qualify for genetic screening under current guidelines
It's less clear-cut for postmenopausal women, study authors say
Prospective study in heavily treated population is warranted, researcher says
High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib
Responses in a fourth of patients, clinical benefit in up to 90%
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
Significant PFS results demonstrated in NORA trial don't extend to overall survival
Mirvetuximab soravtansine produced responses in almost a third of patients in pivotal trial
One in five patients experienced changes in their care plan
PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says
Post-hoc data from SOLO3 show diverging results based on prior lines of therapy
A response to "practice-changing data" in the first- and second-line setting
Results from SOLO-1 and PAOLA-1 show "clinically meaningful" long-term results with olaparib
